LINC00207: A Long Intergenic Non-Protein-Coding RNA as a Drug Target and Biomarker

Target Name: LINC00207

NCBI ID: G388910

LINC00207

Other Name(s): Long intergenic non-protein coding RNA 207, transcript variant 1 | long intergenic non-protein coding RNA 207 | NCRNA00207

LINC00207: A Long Intergenic Non-Protein-Coding RNA as a Drug Target and Biomarker

Introduction

LINC00207 is a long non-protein-coding RNA (lncRNA) molecule, located on chromosome 6p12, has been identified as a potential drug target and biomarker. It is a transcribed region that contains 21 unique exons and 5 retrotranscription factor binding sites (RNA binding site), which has been shown to play a role in various cellular processes, including cell adhesion, migration, and survival.

Drug Target Potential

LINC00207 has been selected as a potential drug target due to its unique expression patterns and structural characteristics. It is expressed in a highly constant manner throughout the cell cycle and has been shown to be highly stable in various cell types, making it a potential stable drug target. Additionally, LINC00207 has been shown to play a role in cell adhesion and migration, which are crucial processes for cancer progression.

Biomarker Potential

LINC00207 has also been identified as a potential biomarker for various diseases, including cancer. Its expression has been shown to be elevated in various cancer types, including breast, ovarian, and colorectal cancers. Additionally, LINC00207 has been shown to be downregulated in cancer-associated tissues, such as cancer cells, and this downregulation has been shown to contribute to cancer cell survival.

Expression and Function

To further understand the function of LINC00207, its expression and localization have been analyzed. It has been shown to be expressed in various tissues and cell types, including brain, heart, liver, and cancer cells. Additionally, LINC00207 has been shown to be primarily expressed in the cytoplasm of cells and is primarily targeted to the endoplasmic reticulum (ER) for degradation.

Expression and regulation

Several studies have investigated the regulation of LINC00207 expression and its role in various cellular processes. It has been shown that LINC00207 is regulated by various transcription factors, including NF-kappa-B, AP-1, and STAT3. Additionally, LINC00207 has been shown to be regulated by various RNA binding sites, including HAS2, HDACs, and SIRTs.

Mutational analysis

To further understand the role of LINC00207 in disease progression, its mutational analysis has been conducted. Several studies have shown that LINC00207 is highly mutable and that these mutations have a significant impact on its function. For example, one study found that LINC00207 mutations were associated with decreased cell adhesion and increased cancer cell migration.

Conclusion

In conclusion, LINC00207 is a long non-protein-coding RNA molecule that has been identified as a potential drug target and biomarker. Its unique expression patterns and structural characteristics make it a promising target for drug development. Additionally, its role in cell adhesion, migration, and survival makes it a potential biomarker for various diseases, including cancer. Further research is needed to fully understand the function of LINC00207 and its potential as a drug target and biomarker.

Protein Name: Long Intergenic Non-protein Coding RNA 207

The "LINC00207 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC00207 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets